International Journal of
Reproductive Biomedicine
Tue, Dec 31, 2024
[Archive]
Volume 14, Issue 9 (9-2016)
IJRM 2016, 14(9): 557-566 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alyasin A, Mehdinejadiani S, Ghasemi M. GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. IJRM 2016; 14 (9) :557-566
URL: http://ijrm.ir/article-1-786-en.html
URL: http://ijrm.ir/article-1-786-en.html
1- Department of Endocrinology and Infertility, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Anatomy, School of Medicine, Tehran University of Medical Science, Tehran, Iran
3- Department of Endocrinology and Infertility, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran ,drghasemim@yahoo.com
2- Department of Anatomy, School of Medicine, Tehran University of Medical Science, Tehran, Iran
3- Department of Endocrinology and Infertility, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran ,
Abstract: (3774 Views)
Routinely, a bolus of 5.000-10.000 IU human chorionic gonadotropin (hCG) is usedfor the final follicular maturation and ovulation as a standard method. HCG has thesame effect of luteinizing hormone (LH) with long half-life. It has the longlutheotrophic effect which increases the risk of ovarian hyper stimulation syndrome(OHSS). Recently, gonadotropin-releasing hormone agonist (GnRH-a) trigger hasbeen used for the induction of final follicular maturation and ovulation with the aimof reducing the OHSS risk. Several studies have shown that the releases ofendogenous follicular stimulating hormone (FSH) and LH after administration ofGnRH agonist in in vitro fertilization (IVF) cycles are able to precede the finalfollicular maturation leading to removal of fertile oocyte with normal developmentof the embryo and ultimately pregnancy. But based on the results of some studies,using GnRH-a trigger leads to defect luteal-phase resulting to reduce theimplantation and clinical pregnancy rates and also increase abortion in fresh embryotransfer cycles compared to routine IVF cycle with hCG triggering . Also, in recentyears, studies have continued to modify the luteal phase support, so that the freshembryo transfer is possible too. In this review, we examined the benefits, problems,and also ways to reform GnRH agonist triggering complications
Type of Study: Original Article |
References
1. Hoff JD, Quigley ME, Yen SS. Hormonal Dynamics at Midcycle: A Reevaluation. J Clin Endocrinol Metab 1983; 57: 792-796. [DOI:10.1210/jcem-57-4-792]
2. Casper RF. Basic understanding of gonadotropin-releasing hormone-agonist triggering. Fertil Steril 2015; 103: 867-879. [DOI:10.1016/j.fertnstert.2014.12.129]
3. Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online 2014; 29: 274-280. [DOI:10.1016/j.rbmo.2014.05.008]
4. Nakano R, Mizuno T, Kotsuji F, Katayama K, Washio M, Tojo S. "Triggering" of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstet Gynecol Scand 1973; 52: 269-272. [DOI:10.3109/00016347309158325]
5. Taylor JE, Miller BT, Gray KD, Scott RT, Catherino WH, Segars JH. The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist. Fertil Steril 2010; 93: 1668-1675. [DOI:10.1016/j.fertnstert.2008.12.047]
6. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213-220. [DOI:10.1016/S0015-0282(16)54474-4]
7. Humaidan P, Bredkjær HE, Westergaard LG, Andersen CY. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847-854. [DOI:10.1016/j.fertnstert.2008.12.042]
8. Humaidan P, Polyzos N, Alsbjerg B, Erb K, Mikkelsen A, Elbaek H, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013; 28: 2511-2521. [DOI:10.1093/humrep/det249]
9. Humaidan P, Bredkjær HE, Bungum L, Bungum M, Grøndahl M, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20: 1213-1220. [DOI:10.1093/humrep/deh765]
10. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20: 783-788. [DOI:10.1016/j.rbmo.2010.03.004]
11. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014; 31: 927-932. [DOI:10.1007/s10815-014-0248-6]
12. Andersen CY. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online 2002; 5: 232-239. [DOI:10.1016/S1472-6483(10)61826-3]
13. Karakji EG, Tsang BK. Regulation of rat granulosa cell plasminogen activator system: influence of interleukin-1 beta and ovarian follicular development. Biol Reprod 1995; 53: 1302-1310. [DOI:10.1095/biolreprod53.6.1302]
14. Richards JS, Hernandez-Gonzalez I, Gonzalez-Robayna I, Teuling E, Lo Y, Boerboom D, et al. Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation. Biol Reprod 2005; 72: 1241-1255. [DOI:10.1095/biolreprod.104.038083]
15. Eppig JJ. FSH stimulates hyaluronic acid synthesis by oocyte–cumulus cell complexes from mouse preovulatory follicles. Nature 1979; 281: 483-484. [DOI:10.1038/281483a0]
16. Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2011; 95: 1655-1660. [DOI:10.1016/j.fertnstert.2011.01.019]
17. Zelinski-Wooten M, Hutchison J, Hess D, Wolf D, Stouffer R. Endocrinology: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 1995; 10: 1658-1666. [DOI:10.1093/oxfordjournals.humrep.a136151]
18. moedemhe D, Sigue A, Pacpaco E, Olazo A. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 1991; 55: 328-332. [DOI:10.1016/S0015-0282(16)54125-9]
19. Andersen CY, Leonardsen L, Ulloa-Aguirre A, Barrios-De-Tomasi J, Moore L, Byskov A. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 1999; 5: 726-731. [DOI:10.1093/molehr/5.8.726]
20. Shapiro BS, Andersen CY. Major drawbacks and additional benefits of agonist trigger-not ovarian hyperstimulation syndrome related. Fertil Steril 2015; 103: 874-878. [DOI:10.1016/j.fertnstert.2015.01.035]
21. Fauser B, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709-715. [DOI:10.1210/jcem.87.2.8197]
22. De Ziegler D, Shoham Z. Triggering of ovulation with GnRHa in ART: worldwide feedback on an emerging new option with great potential. Available at: .
23. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. Fertil Steril 2014; 101: 1008-1011. [DOI:10.1016/j.fertnstert.2014.01.019]
24. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84-91. [DOI:10.1016/j.fertnstert.2007.02.002]
25. Griffin D, Engmann L, Budinetz T, Kummer N, Nulsen J, Benadiva C. Dual trigger with gonadotropin releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) for the treatment of 'immature oocyte syndrome'(IOS). Fertil Steril 2012; 98: S156. [DOI:10.1016/j.fertnstert.2012.07.577]
26. Humaidan P, Kol S, Papanikolaou E. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-524. [DOI:10.1093/humupd/dmr008]
27. Cerrillo M, Pacheco A, Rodríguez S, Gómez R, Delgado F, Pellicer A, et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril 2011; 95: 2517-2519. [DOI:10.1016/j.fertnstert.2010.12.054]
28. D'Angelo A BJ, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; 15: CD002811. [DOI:10.1002/14651858.CD002811.pub3]
29. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010; 94: 1111-1114. [DOI:10.1016/j.fertnstert.2009.10.034]
30. Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment of follicle size on oocyte developmental competence. Fertil Steril 2008; 90: 684-690. [DOI:10.1016/j.fertnstert.2007.02.011]
31. Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril 2015; 103: 870-873. [DOI:10.1016/j.fertnstert.2015.02.004]
32. Haas J, Ophir L, Barzilay E, Yerushalmi GM, Yung Y, Kedem A, et al. Gnrh agonist vs hCG for triggering of ovulation-differential effects on gene expression in human granulosa cells. PLoS One 2014; 9: e90359. [DOI:10.1371/journal.pone.0090359]
33. Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, et al. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2013; 100: 742-747. [DOI:10.1016/j.fertnstert.2013.05.028]
34. Kolibianakis E, Collins J, Tarlatzis B, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651-671. [DOI:10.1093/humupd/dml038]
35. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod Biomed Online 2013; 26: 226-230. [DOI:10.1016/j.rbmo.2012.11.002]
36. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 2014; 29: 541-544. [DOI:10.1016/j.rbmo.2014.07.022]
37. Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Hum Reprod 2011; 26: 2874-2877. [DOI:10.1093/humrep/der220]
38. Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 2013; 28: 2529-2536. [DOI:10.1093/humrep/det304]
39. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011; 26: 3437-3442. [DOI:10.1093/humrep/der333]
40. Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril 2012; 97: 527-528 [DOI:10.1016/j.fertnstert.2011.12.010]
41. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011; 26: 2593-2597. [DOI:10.1093/humrep/der251]
42. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. Fertil Steril 2011; 96: 344-348. [DOI:10.1016/j.fertnstert.2011.05.050]
43. Fatemi H, Popovic-Todorovic B. Implantation in assisted reproduction: a look at endometrial receptivity. Reprod Biomed Online 2013; 27: 530-538. [DOI:10.1016/j.rbmo.2013.05.018]
44. Farhi J, Haroush AB, Andrawus N, Pinkas H, Sapir O, Fisch B, et al. High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation. Reprod Biomed Online 2010; 21: 331-337. [DOI:10.1016/j.rbmo.2010.04.022]
45. Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2012; 98: 368-377. [DOI:10.1016/j.fertnstert.2012.05.019]
46. Tomás C, Alsbjerg B, Martikainen H, Humaidan P. Pregnancy loss after frozen-embryo transfer-a comparison of three protocols. Fertil Steril 2012; 98: 1165-1169. [DOI:10.1016/j.fertnstert.2012.07.1058]
47. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004; 81: 1-5. [DOI:10.1016/j.fertnstert.2003.05.032]
48. Belva F, Henriet S, Van den Abbeel E, Camus M, Devroey P, Van der Elst J, et al. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008; 23: 2227-2238. [DOI:10.1093/humrep/den254]
49. Pinborg A, Loft A, Henningsen AKA, Ziebe S. Does assisted reproductive treatment increase the risk of birth defects in the offspring? Acta Obstet Gynecol Scand 2012; 91: 1245-1246. [DOI:10.1111/j.1600-0412.2012.01500.x]
50. Henningsen AKA, Romundstad LB, Gissler M, Nygren KG, Lidegaard Ø, Skjaerven R, et al. Infant and maternal health monitoring using a combined Nordic database on ART and safety. Acta Obstet Gynecol Scand 2011; 90: 683-691. [DOI:10.1111/j.1600-0412.2011.01145.x]
51. Andersen CY, Andersen KV. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online 2014; 28: 552-559. [DOI:10.1016/j.rbmo.2014.01.012]
52. Kolibianakis E, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887-2892. [DOI:10.1093/humrep/dei150]
53. Griesinger G, Diedrich K, Devroey P, Kolibianakis E. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12: 159-168. [DOI:10.1093/humupd/dmi045]
54. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003; 14: 236-242. [DOI:10.1016/S1043-2760(03)00075-4]
55. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001; 16: 663-667. [DOI:10.1093/humrep/16.4.663]
56. Tavaniotou A, Devroey P. Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles. Fertil Steril 2003; 80: 654-655. [DOI:10.1016/S0015-0282(03)00789-1]
57. Sugino N, Kashida S, Takiguchi S, Karube A, Kato H. Expression of Vascular Endothelial Growth Factor and Its Receptors in the Human Corpus Luteum during the Menstrual Cycle and in Early Pregnancy 1. J Clin Endocrinol Metab 2000; 85: 3919-3924.
58. Licht P, Russu V, Wildt L, editors. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 2000; 19: 37-47. [DOI:10.1055/s-2001-13909]
59. Wang T-H, Horng S-G, Chang C-L, Wu H-M, Tsai Y-J, Wang H-S, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002; 87: 3300-3308. [DOI:10.1210/jcem.87.7.8651]
60. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186-4192. [DOI:10.1210/jc.2002-021953]
61. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006; 86: 1682-1687. [DOI:10.1016/j.fertnstert.2006.05.049]
62. Beall S, Moon K, Widra E, Segars J, Chang F, Richter K. Human chorionic gonadotropin (hCG) re-trigger following a poor response to leuprolide acetate (LA) trigger is not associated with poor in vitro fertilization (IVF) treatment outcomes. Fertil Steril 2012; 98: S52. [DOI:10.1016/j.fertnstert.2012.07.187]
63. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropin-releasing hormone agonist. Fertil Steril 2011; 95: 826-828. [DOI:10.1016/j.fertnstert.2010.09.009]
64. Chen S-L, Ye D-S, Chen X, Yang X-H, Zheng H-Y, Tang Y, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod 2012; 27: 1351-1356. [DOI:10.1093/humrep/des049]
65. Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006; 13: 639-644. [DOI:10.1016/S1472-6483(10)60653-0]
66. Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril 2015; 103: 879-885. [DOI:10.1016/j.fertnstert.2015.01.034]
67. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011; 95: 2715-2717. [DOI:10.1016/j.fertnstert.2011.03.109]
68. Iliodromiti S, Lan VTN, Tuong HM, Tuan PH, Humaidan P, Nelson SM. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. J Ovarian Res 2013; 6: 1-9. [DOI:10.1186/1757-2215-6-93]
69. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21: 1260-1265. [DOI:10.1093/humrep/dei475]
70. Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril 2008; 89: 554-561. [DOI:10.1016/j.fertnstert.2007.04.006]
71. Pritts E, Atwood A. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002; 17: 2287-2299. [DOI:10.1093/humrep/17.9.2287]
72. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2015; 10: CD009154.
73. Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril 2010; 93: 428-436. [DOI:10.1016/j.fertnstert.2009.02.033]
74. Humaidan P, Bungum L, Bungum M, Andersen CY. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173-178. [DOI:10.1016/S1472-6483(10)60612-8]
75. Humaidan P, Thomsen LH, Alsbjerg B. GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. Hum Reprod 2013; 28: 2593-2594. [DOI:10.1093/humrep/det287]
76. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011; 95: 1174-1177. [DOI:10.1016/j.fertnstert.2010.09.023]
77. Hernández ER, Gómez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril 2009; 91: 1358-1361. [DOI:10.1016/j.fertnstert.2008.03.077]
78. Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril 2009; 91: 1526-1528. [DOI:10.1016/j.fertnstert.2008.08.118]
79. Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011; 95: 2125. [DOI:10.1016/j.fertnstert.2011.01.030]
80. Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet 2012; 29: 503-505 [DOI:10.1007/s10815-012-9752-8]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
